Form 4: Chimerix COO Thomas Riga Disposes of Shares and Options Following Merger with Jazz Pharmaceuticals

Thomas Riga, COO and CCO of Chimerix, reports the disposal of common stock and stock options following the merger with Jazz Pharmaceuticals, as per the terms of the merger agreement.

Summary

• Thomas Riga, the COO and CCO of Chimerix, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the disposal of 60,828 shares of common stock at $8.55 per share due to the merger with Jazz Pharmaceuticals.
• The merger agreement stipulated that outstanding shares would be exchanged for $8.55 per share.
• Outstanding restricted stock units (RSUs) were cancelled and converted into the right to receive a cash payment based on the offer price.
• In-the-money stock options were accelerated, vested, and then cancelled in exchange for a cash payment representing the difference between the offer price and the exercise price.
• Riga also disposed of employee stock options for 800,000 shares with an exercise price of $1 and 325,000 shares with an exercise price of $3.66.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports the execution of a previously announced merger agreement. There are no indications of unexpected positive or negative outcomes.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects the completion of a merger in the pharmaceutical industry, where acquisitions are common for companies looking to expand their product portfolios or pipelines.

Stakeholder Impact

• Shareholders received $8.55 per share as per the merger agreement.
• Employees with stock options and RSUs received cash payments based on the terms of the merger agreement.

Key Dates

Keywords

Chimerix, Jazz Pharmaceuticals, Merger, Form 4, Beneficial Ownership, Stock Options, Thomas Riga, Shares, RSUs